The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT. (Q51804258)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 June 2013

Language	Label	Description	Also known as
English	The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.	scientific article published on 17 June 2013

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

stem cell transplantation

1 reference

based on heuristic

inferred from title

follicular lymphoma

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Noel Jean Milpied

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

S P Robinson

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

C Canals

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

J J Luang

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

H Tilly

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

C Crawley

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

J Y Cahn

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

D Pohlreich

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

S Le Gouill

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

P Biron

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

S Maury

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

A Rambaldi

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

J Maertens

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

S Capria

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

P Colombat

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

S Montoto

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

A Sureda

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

language of work or name

0 references

publication date

17 June 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Bone Marrow Transplantation

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

48

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1409-1414

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23771004%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

https://scigraph.springernature.com/pub.10.1038/bmt.2013.83

0 references

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Myelodysplastic syndrome and acute myeloid leukemia after autotransplantation for lymphoma: a multicenter case-control study.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: long-term follow-up from two prospective multicenter trials.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-Grade Lymphoma Study Group.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Donor lymphocyte infusions can result in sustained remissions in patients with residual or relapsed lymphoid malignancy following allogeneic haemopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Graft-versus-lymphoma effect of donor lymphocyte infusion in indolent lymphomas relapsed after allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

T-cell-depleted reduced-intensity transplantation followed by donor leukocyte infusions to promote graft-versus-lymphoma activity results in excellent long-term survival in patients with multiply relapsed follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

21 January 2018

Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lympho

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

High Response Rate to Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Indolent Non-Hodgkin Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of in vivo T-cell depletion on reduced-intensity conditioning allogeneic stem cell transplantation from HLA-identical siblings in patients with follicular lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory foll

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2013.83

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51804258&oldid=1521641256"